CC0651 is primarily investigated for its potential in cancer research. It functions as a selective inhibitor of Cdc34, an enzyme involved in the ubiquitin-proteasome pathway, which regulates protein degradation in cells. By inhibiting Cdc34, CC0651 disrupts the degradation of specific proteins, leading to the accumulation of cell cycle regulators. This mechanism makes it a promising candidate for studying cancer cell proliferation and developing targeted therapies. Additionally, its role in modulating protein stability provides insights into cellular processes and potential treatments for diseases linked to protein dysregulation. Research is ongoing to explore its efficacy and safety in preclinical models.